Opinion|Videos|February 21, 2025
Latest ASH Updates: Clinical Use of BTK Inhibitors in Management of CLL and MCL
Panelists discuss exciting updates on Bruton tyrosine kinase (BTK) inhibitors from the 2024 American Society of Hematology (ASH) Annual Meeting and Exposition, highlighting emerging data that may refine their use in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), particularly in optimizing treatment duration and sequencing to improve patient outcomes.
Advertisement
Episodes in this series
- Were there any particularly exciting updates or data presented at ASH 2024 that could influence how BTK inhibitors are used in clinical practice for CLL and MCL?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
5 Things to Know About Retatrutide, the "Trillion-Dollar" Drug
2
Retina Specialists Favor Efficacy Over Risk in Geographic Atrophy Care
3
ICER Draft Flags High Cost of New Hypertension Drug Class
4
Iberdomide Approval Elevates MRD’s Role in Myeloma: Prerna Mewawalla, MD
5